It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Salivary gland squamous cell carcinomas (SG-SCCs) constitute a rare type of head and neck cancer which is linked to poor prognosis. Due to their low frequency, the molecular mechanisms responsible for their aggressiveness are poorly understood. In this work we studied the role of the phosphatase DUSP1, a negative regulator of MAPK activity, in controlling SG-SCC progression. We generated DUSP1 KO clones in A253 human cells. These clones showed a reduced ability to grow in 2D, self-renew in ECM matrices and to form tumors in immunodeficient mice. This was caused by an overactivation of the stress and apoptosis kinase JNK1/2 in DUSP1−/+ clones. Interestingly, RNAseq analysis revealed that the expression of SOX2, a well-known self-renewal gene was decreased at the mRNA and protein levels in DUSP1−/+ cells. Unexpectedly, CRISPR-KO of SOX2 did not recapitulate DUSP1−/+ phenotype, and SOX2-null cells had an enhanced ability to self-renew and to form tumors in mice. Gene expression analysis demonstrated that SOX2-null cells have a decreased squamous differentiation profile -losing TP63 expression- and an increased migratory phenotype, with an enhanced epithelial to mesenchymal transition signature. In summary, our data indicates that DUSP1 and SOX2 have opposite functions in SG-SCC, being DUSP1 necessary for tumor growth and SOX2 dispensable showing a tumor suppressor function. Our data suggest that the combined expression of SOX2 and DUSP1 could be a useful biomarker to predict progression in patients with SG-SCCs.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details

1 IdiPAZ, Laboratory of Translational Research in Maxillofacial Surgery and Head and Neck Cancer, Madrid, Spain (GRID:grid.81821.32) (ISNI:0000 0000 8970 9163); Instituto de Investigaciones Biomédicas CSIC/UAM and CIBER de Enfermedades Raras (CIBERER), Madrid, Spain (GRID:grid.452372.5) (ISNI:0000 0004 1791 1185)
2 IdiPAZ, Laboratory of Translational Research in Maxillofacial Surgery and Head and Neck Cancer, Madrid, Spain (GRID:grid.81821.32) (ISNI:0000 0000 8970 9163)
3 Instituto de Investigaciones Biomédicas CSIC/UAM and CIBER de Enfermedades Raras (CIBERER), Madrid, Spain (GRID:grid.452372.5) (ISNI:0000 0004 1791 1185)
4 University Hospital La Paz, Medical Oncology Department, Madrid, Spain (GRID:grid.81821.32) (ISNI:0000 0000 8970 9163)
5 IdiPAZ, Laboratory of Translational Research in Maxillofacial Surgery and Head and Neck Cancer, Madrid, Spain (GRID:grid.81821.32) (ISNI:0000 0000 8970 9163); University Hospital La Paz, Oral and Maxillofacial Surgery Department, Madrid, Spain (GRID:grid.81821.32) (ISNI:0000 0000 8970 9163)
6 Instituto de Salud Carlos III and CIBER de Enfermedades Raras (CIBERER), Madrid, Spain (GRID:grid.413448.e) (ISNI:0000 0000 9314 1427)